While the standard of care for all patients with severe hemophilia A is FVIII replacement therapy with clotting factor concentrates, or other hemostatic products, the ability to increase protection from bleeds by achieving higher sustained levels of FVIII activity remains a critical need for patients that is recognized by the World Federation of Hemophilia [1, 9, 14]. The gene discussed is F8; the disease is hemophilia A.